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Abstract
Folate is a member of vitamin B family and plays an essential role in cell survival by
participating in the biosynthesis of nucleic and amino acids. Receptors folic acid are frequently
over expressed on epithelial cancer cells. These receptors are believed to serve as a receptormediated transport system of folic acid into cancer cells and cells associated with inflammation.
Interesting, most normal cells in the body have lower frequency of these receptors. Based on
these attributes, folate based drug delivery, imaging systems, and diagnostic systems are in
several stages of development worldwide.
In this current project, we have characterized the affinity of the proprietary folate PEGbiotin-fluorescein- (FPBF) conjugate synthesized by Dr. Walter Henne. We have successfully
purified and characterized FPBF capture ligand using LC/MS. Further, affinity studies of FPFB
towards Streptavidin coated Dynabeads was carried out utilizing fluorescein microscopy. It was
demonstrated that the conjugate has site specific interaction toward the Streptavidin coated
Dynabeads, a much important characteristic for the effective cancer cell capture. The
inexpensive and previously produced folate probe may be substituted for the more costly and
cumbersome antibody based ligands, which are typically used for this method of drug delivery
system to treat cancer. This method significantly reduces false positive events associated with
non-specific binding and capture of non-targeted cells (a problem associated with the
aforementioned affinity capture protocols).
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Introduction
Folate receptor-targeted anti-cancer agent delivery:
Despite the fact that there have been significant developments in anti-cancer technology, such as
radiotherapy, chemotherapy and hormone therapy, cancer still remains as the second leading
cause of death following heart disease in the United States (1). Most often, the main cancer
treatment is chemotherapy utilizing highly potent drugs, which include mitomycin, paclitaxel
and camptothecin. In many cases, these chemotherapeutic agents show a doseresponsive effect,
and cell kill is proportional to drug exposure (2). Highly aggressive style of dosing is thus
necessary to eradicate neoplasms; however, high-dose chemotherapy is hindered by poor
selectivity for cancer cells and severe toxicity to normal cells (3).
Clearly, this lack of tumor-specific treatment is one of the many hurdles that needs to be
overcome by current chemotherapy. An ideal solution to current chemotherapy limitations
would be to deliver a biologically effective concentration of anti-cancer agents to the tumor
tissues with very high specificity. In order to reach this ultimate goal, tremendous amount of
efforts were undertaken to develop tumor-selective drugs by conjugating anti-cancer drugs to
hormones, antibodies and vitamin derivatives (4). Among them, one low molecular weight
vitamin compound, folic acid, shows a great deal of promise as a tumor-homing agent.
Folate (Figure 1) is a member of vitamin B family and plays an essential role in cell
survival by participating in the biosynthesis of nucleic and amino acids (5). This essential
vitamin is also a high affinity ligand that enhances the differential specificity of conjugated anti6

cancer drugs by targeting folate receptor (FR)-positive cancer cells (6). The FR, a tumor
associated glycosylphosphatidylinositol anchored protein, can actively internalize bound folates
and folate conjugated compounds via receptor-mediated endocytosis (7, 8). It has been found
that FR is up-regulated in more than 90% of non-mucinous ovarian carcinomas. It is also found
at high to moderate levels in kidney, brain, lung, and breast carcinomas while it occurs at very
low levelsin most normal tissues (9). The FR density also appears to increase as the stage of the
cancer increases (10).
Exploiting the above-mentioned facts, it is hypothesized that folate conjugation to anti-cancer
drugs will improve drug selectivity and decrease negative side effects. Based on the previous
research that folate conjugation allows a drug molecule to target and become endocytosed into
FR-positive cancer cells, numerous types of anti-cancer drugs were conjugated and evaluated for
their biological activity (11). Particularly, folate-mitomycin C conjugates, EC72 and EC118,
were found to be highly cytotoxic and outstandingly selective for FR-positive M109 cells (12,
13). In addition, EC72 and EC118 significantly extended lifespan of nu/nu mice with human
KB xenografts without evidence of toxicity to major organs or delayed cumulative
myelosuppression, the most common negative side effect of mitomycinC (14). Furthermore,
combination therapy with paclitaxel produced a synergistic anti-tumor effect without any
apparent adverse effects, suggesting a possibility of adjuvant use of folate conjugated drugs.
Overall, performance of EC72 and EC118, both in vitro and in vivo, proves that folate
conjugation enhances drug specificity thereby reducing lethal toxicity
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Streptavidin- Biotin affinity Capture
Streptavidin is a tetrameric protein that binds biotin with an affinity that is among the highest
displayed for noncovalent interactions between a ligand and protein (Ka 1013 M-1) (15). The xray crystallographic studies of Streptavidin by Weber et al. (16, 17) and Hendrickson et
al.(18,19) have provided considerable insight into the structural origins of the high affinity of the
biotin-Streptavidin system. The structure-function origins of this unusually high-affinity
interaction, however, have yet to be elucidated. Streptavidin displays a number of commonly
observed molecular recognition motifs in the interaction with biotin: these include hydrophobic
and Vander Waals dispersive interactions that are largely mediated by the aromatic side chains of
Trp residues (20-21), hydrogen bonding networks mediated by donor/acceptor side chains (2223), and disorder-to-order transitions mediated by the ordering of surface polypeptide loops upon
ligand binding (24-25).
Dynabeads Ligand Affinity Capture
The strength and specificity of the Streptavidin and biotin interaction has led it to be one of the
most widely used affinity pairs in molecular, immunological, and cellular assays. Traditional
methodologies for cell separation involve various forms of centrifugation and/or filtration.
These techniques, while useful, have many drawbacks including low specificity without costly
instrumentation development(26), high levels of sheer force leading to decreased number of
active cells post separation, costly consumables, and multiple time consuming steps when
dealing with complex matrices, such as whole blood(27). Modern techniques have been
developed which utilize paramagnetic properties of metals. These techniques rely on the cells of
8

interest containing either intrinsic magnetic properties or are tagged with a magnetic label for
separation (for a thorough review of magnetic cell separation techniques see reference 28). Of
the two techniques, cell types containing intrinsic magnetic properties are extremely limited with
red blood cells (erythrocytes) and magnetotactic bacteria being the only cell types existing in
nature. Magnetic labeling, however, is limited only by the existence of an appropriate cell
surface target and some form of affinity ligand with bound paramagnetic particle. After
successful attachment of paramagnetic particles, cells can then be separated using either flowthrough or batch magnetic separators.
Dynabeads® M-280 Streptavidin (Invitrogen™)
These uniform and super paramagnetic beads are 2.8 µm in diameter, with a monolayer –
not a multilayer - of recombinant Streptavidin covalently coupled to the surface and further
blocked with BSA. The monolayer of Streptavidin leaves the vast majority of the biotin binding
sites sterically available for binding, not only of free biotin, but also for binding of biotinylated
ligands/targets. They show rapid liquid-phase reaction kinetics. Their specific and defined
surface allow for efficient capture, separation and downstream handling. The Streptavidin
monolayer ensures negligible leakage, and the lack of excess adsorbed Streptavidin ensures
batch consistency and reproducibility. The reduced particle variability would give reliable and
reproducible results on which studies, diagnostic assays and therapeutic protocols may be
established.
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In this report, we describe the development of a folate PEG biotin fluorescein (FFBF),
Figure 3, its purification using Preparative HPLC, its affirmation by LCMS and its site-specific
affinity behavior towards Dynabeads. The fluorescein fluorophore in the folate PEG biotin chain
was exploited for assessment and confirmation of the site-specific nature of the ligand and beads
interaction via a secondary detection scheme (i.e. fluorescence microscopy). This principle can
be extended for isolation and detection of folate receptor positive cancer cells. This method
significantly reduces false positive events associated with non-specific binding and capture of
non-targeted cells (a problem associated with affinity capture protocols).

Materials & Methods
Preparative HPLC of Folate-PEG-Biotin Fluorescein
The proprietary Folate- -PEG -Biotin Fluorescein molecule prepared by Dr. Walter
Henne was dissolved in DMSO and centrifuged for 10 minutes. The preparative HPLC was then
carried out with a Hewlett Packard, series 1050 HPLC equipped with a Diode array detector and
ChemStation software.
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The following instrument and method parameters were utilized:
Column

Rigel 5µm C18 10X250mm
from Stellar Phases Inc. (cat.#: 5C18-10-250)

Solvent A

10 mM Ammonium Bicarbonate Buffer (NH 4 HCO 3 )

Solvent B

Acetonitrile (ACN)

Flow Rate 1ml/min
Run Time

•

100 min

Gradient:
Time (min) NH 4 HCO 3 (%) ACN (%)
0
99
1
30
70
30
35
40
60
40
10
90
45
10
90
60
99
1
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LC/MS Analysis
The purified FPBF sample was then analyzed using an Agilent 1100 series LC/MSD Trap
for identity and purity confirmation. The instrument uses Agilent ChemStation and Bruker
software.
The following instrument and method parameters were utilized:
Column

Eclipse XDB C18

Solvent

Methanol and Water

Injection volume 5µl
Flow Rate

0.5ml

Scan Range

500-1500 m/z

Mode

Negative ion

Gradient:
Time (min) Methanol (%)
0
30
1
50
2
70
3
90
12

Lyophilization:
The purified compound was lyophilized to get rid of the solvent (DMSO) used for preparative
HPLC. The vial with FPBF was frozen in liquid Nitrogen tank. With a porous cap, it was then
subjected to high vacuum conditions in High vacuum refrigerated conditioning trap
(SAVANT). The setup was kept undisturbed overnight and the solvent was sublimed.
Affinity studies of FPBF towards Streptavidin Coated Magnetic Beads
•

Dynabeads® M-280 Streptavidin manufactured by Invitrogen™ -One mg of Dynabeads®
M-280 Streptavidin typically binds 650-900 pmoles free biotin.

•

Phosphate Buffered Saline: 1X from Cellgro (Mediatech, Inc) without Calcium and
Magnesium, Cat. No. 21-040-CV

Purified Sample of FPBF was dissolved in PBS to produce 12µM concentration of ligand. To
10µL of this, 30µL Dynabeads were added and the final volume was made up to 280µL using
PBS. The mixture was homogenized using HulaMixer™ for 10 minutes for uniform binding and
allowed to stand in a magnetic stand for 10 minutes. After washing the beads and captured FPBF
with PBS three times, small amount of sample was spread on the cover slide and observed under
Fluorescence Microscope.
A control slide was also prepared with a competent Folate PEG biotin (96µM) incubated with
Dynabeads prior to addition of FPBF sample. Similar steps of incubation, mixing and washing
were performed. The sample and control were prepared at the same time to maintain accuracy with
respect to time and working conditions.
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Results and Discussion
The chromatogram(figure 4) obtained from the Preparative HPLC (Hewlett Packard
series 1050 HPLC) showed a sharp and intense peak at 29.40 minutes monitored at 365nm
wavelength. The other small and irregular peaks at 27.5, 28.0, 29.0,30.5,31.0 and 32.0 minutes
are from impurities and the intense, sharp peak at 29.40 minutes is due to pure FPBF, which was
later verified by diode array and LCMS.
Further, the peak at 29.40 minutes was coordinated and the purified FPBF was collected
to be analyzed by Agilent Technologies, 1100 series LC/MSD Trap for identity confirmation.
The diode array response (LC chromatogram- figure 5) showed a prominent peak approximately
at 5.40 minutes monitored at 280nm. The presence of only one peak was confirmation of the
purity of the compound.
A diode array spectrum was scanned at retention of 5.40 minutes to confirm folate peak.
The diode array spectrum gave rise to a typical double event with maximum absorbance at
approximately 280 and 360 nm, which is indicative of folate (Figure 6). In addition, a typical
peak associated with fluorescein was observed at approximately 480-490 nm (Figure 6).
Combining data from HPLC and DAD leads to confirmation of a relatively pure compound.
Total ion chromatogram showed a peak at 5.3-5.70 minutes (Figure 7). Mass spectrum of
this retention time showed a single molecular ion peak of FPBF at m/z = 1384.8 and doubly
charged ionic peak at m/z = 692 (Figure 8). The calculated molecular mass of FPBF is 1386.6

14

Da. Since the run was in negative ion mode, the observed peaks in the mass spectrum correspond
to M* – H+ and M** – H+ ion species.
Affinity studies of FPBF with the Dynabeads showed a colony of well-distributed beads
(Figures 8A, 10A) under Light microscopy. However, the fluorescence Microscopy showed the
fluorescence of the beads in the sample but not in the control (figures 9B,10B). The affinity of
the FPBF towards the Dynabeads can be confirmed as site specific as there is no fluorescence in
control, which was incubated with FPB competitor prior to addition of FPBF (figures 9B, 10B).

Conclusion
Folate PEG biotin fluorescein was purified by Preparative HPLC and characterization of
the proprietary FPBF yielded a high purity compound with confirmed components of folate and
fluorescein accompanied by structural confirmation via mass spectrometry. The affinity studies
of Dynabeads and purified Folate PEG biotin fluorescein aided by Fluorescence microscopy,
successfully demonstrated that the conjugate has site specific interaction toward the Streptavidin
coated Dynabeads, a much important characteristic for the effective cancer cell capture. The
inexpensive and previously produced folate probe may be substituted for the more costly and
cumbersome antibody based ligands, which are typically used for this method of drug delivery
system to treat cancer
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Future Studies
Further study of FFPB in the realm of characterization should include additional
structural confirmation utilizing 1H-NMR, 13C-NMR, X-ray diffraction, positive ion-mode mass
spectrometry, differential scanning calorimetry, and thermogravimetric analysis. Due to the
success of FPBF and its affinity characteristics, cell capture studies can be performed which
might replace the expensive antibody mediated cell capture.
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Figure 1: Folic Acid Structure (drawn using ChemBioDraw Ultra v. 11.0.1)
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Figure 2: Folate Receptor-Mediated Endocytosis[1]
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Figure 3: Folate-Fluorescein-PEG-Biotin Bridging Ligand Structure (drawn using
ChemBioDraw Ultra v. 11.0.1)
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Chemical Formula: C67H79N13O16S2
.
Molecular Weight: 1386 6
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Figure 4: Preparative LC chromatogram for Folate- PEG-Biotin- Fluorescein at 280 nm

Figure 5: LCMS analysis (LC chromatogram at 280nm)

Figure 6: Diode Array Spectrum at 5.40 minute Retention time
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Figure 7: LCMS analysis (Total ion chromatogram)

Figure 8: Mass Spectrum for Folate-Fluorescein-PEG-Biotin (Negative Ion mode)
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Figures 9 and 10: Dynabeads Affinity Comparison of FPBF without and with Folate- PEG –
Biotin(control)
9A) Light Microscopy (control)

10A) Light Microscopy (sample)

9B) Fluorescence Microscopy (control)

10B) Fluorecence Microscopy (sample)
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